Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High-Risk Real-World Cohort.

Within 30 days of starting SC furosemide, 10 of 49 analyzed patients (20.4%) had a heart failure hospitalization (primary outcome).

• Single-center retrospective cohort study of HF patients prescribed SC furosemide (Furoscix, 80 mg/10 mL) as an adjunct to oral loop diuretics between May 2023 and 2025.
• Fifty patients met inclusion criteria; one was excluded for incomplete follow-up, leaving 49 analyzed.
• SC furosemide was prescribed as two to three doses per week.

Of the patients hospitalized within 30 days, six had also been hospitalized in the 30 days before initiation, indicating a high-risk baseline cohort.

• Six of the 10 patients with HFH within 30 days had a prior HFH in the preceding 30 days.
• The authors interpret this as suggesting a high-risk baseline population.

The composite endpoint of HFH or urgent care/emergency department visit requiring intravenous diuresis occurred in 16 patients (32.7%).

• The composite was a secondary outcome.
• It included HFH, or urgent care or ED visits requiring intravenous diuresis.

Among patients who avoided hospitalization, median NYHA functional class improved from III to II.

• NYHA class was a secondary outcome.
• The improvement was reported only for patients who avoided hospitalization.

Among patients who avoided hospitalization, mean body weight decreased by 2.6 kg (5.7 lbs).

• Change in body weight was a secondary outcome.
• The weight change was reported among patients who avoided hospitalization.

SC furosemide was well tolerated, with infrequent adverse events and no deaths within 30 days of follow-up.

• No deaths occurred within the 30-day follow-up period.
• Adverse events were described as infrequent.